Comprehensive Analysis of Tumor Necrosis Factor-α-inducible Protein 8-like 2 (TIPE2): A Potential Novel Pan-cancer Immune Checkpoint

Overview

Journal Comput Struct Biotechnol J

Specialty Biotechnology

Date 2022 Oct 3

PMID 36187930

Authors

Kun-Hao Bai

Yi-Yang Zhang

Xue-Ping Li

Xiao-Peng Tian

Meng-Meng Pan

Da-Wei Wang

Yu-Jun Dai

Affiliations

Soon will be listed here.

Abstract

Tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2) is encoded by TNFAIP8L2 and is a newly identified negative regulator of natural and acquired immunity that plays a critical function in maintaining immune homeostasis. Recently, CAR-NK immune cell therapy has been a focus of major research efforts as a novel cancer therapeutic strategy. TIPE2 is a potential checkpoint molecule for immune cell maturation and antitumor immunity that could be used as a novel NK cell-based immunotherapeutic approach. In this study, we explored the expression of TNFAIP8L2 across various tumor types and found that TNFAIP8L2 was highly expressed in most tumor types and correlated with prognosis. Survival analysis showed that TNFAIP8L2 expression was predictive of improved survival in cervical-squamous-cell-carcinoma (CESC), sarcoma (SARC) and skin-cutaneous-melanoma (SKCM). Conversely, TNFAIP8L2 expression predicted poorer survival in acute myeloid leukemia (LAML), lower-grade-glioma (LGG), kidney-renal-clear-cell-carcinoma (KIRC) and uveal-melanoma (UVM). Analysis of stemness features and immune cell infiltration indicated that TNFAIP8L2 was significantly associated with cancer stem cell index and increased macrophage and dendritic cell infiltration. Our data suggest that TNFAIP8L2 may be a novel immune checkpoint biomarker across different tumor types, particularly in LAML, LGG, KIRC and UVM, and may have further utility as a potential target for immunotherapy.

Citing Articles

Zinc finger protein 296 promotes hepatocellular carcinoma progression via intervening interaction between macrophages and B cells.

Xu N, Xiang X, Chen H, Chen Y, Wang S, Guo H Chin J Cancer Res. 2024; 36(5):517-529.

PMID: 39539816 PMC: 11555204. DOI: 10.21147/j.issn.1000-9604.2024.05.05.

TIPE2 inhibits melanoma progression through MEK/ERK signaling.

Gao X, Li Y, Wang C, Zhao G Sci Rep. 2024; 14(1):27736.

PMID: 39532931 PMC: 11557980. DOI: 10.1038/s41598-024-76794-z.

Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies.

Sun W, Hu S, Wang X Cancer Commun (Lond). 2024; 44(9):1071-1097.

PMID: 39073258 PMC: 11492363. DOI: 10.1002/cac2.12587.

Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.

Lin H, Liu C, Hu A, Zhang D, Yang H, Mao Y J Hematol Oncol. 2024; 17(1):31.

PMID: 38720342 PMC: 11077829. DOI: 10.1186/s13045-024-01544-7.

The Future of Checkpoint Inhibitors in Uveal Melanoma: A Narrative Review.

Wang J, Li Z, Yin H Ophthalmol Ther. 2024; 13(5):1103-1123.

PMID: 38498280 PMC: 11039591. DOI: 10.1007/s40123-024-00913-2.

References

Zhang Z, Liu L, Cao S, Zhu Y, Mei Q . Gene delivery of TIPE2 inhibits breast cancer development and metastasis via CD8 T and NK cell-mediated antitumor responses. Mol Immunol. 2017; 85:230-237. DOI: 10.1016/j.molimm.2017.03.007. View

Zeng D, Ye Z, Wu J, Zhou R, Fan X, Wang G . Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer. Theranostics. 2020; 10(15):7002-7014. PMC: 7295060. DOI: 10.7150/thno.46176. View

Nguyen N, Huang K, Zeng H, Jing J, Wang R, Fang S . Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. Nat Nanotechnol. 2021; 16(12):1424-1434. PMC: 8678207. DOI: 10.1038/s41565-021-00982-5. View

Mao X, Ou M, Karuppagounder S, Kam T, Yin X, Xiong Y . Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science. 2016; 353(6307). PMC: 5510615. DOI: 10.1126/science.aah3374. View

Ozga A, Chow M, Luster A . Chemokines and the immune response to cancer. Immunity. 2021; 54(5):859-874. PMC: 8434759. DOI: 10.1016/j.immuni.2021.01.012. View

Dolina J, Van Braeckel-Budimir N, Thomas G, Salek-Ardakani S . CD8 T Cell Exhaustion in Cancer. Front Immunol. 2021; 12:715234. PMC: 8330547. DOI: 10.3389/fimmu.2021.715234. View

Ott M, Prins R, Heimberger A . The immune landscape of common CNS malignancies: implications for immunotherapy. Nat Rev Clin Oncol. 2021; 18(11):729-744. PMC: 11090136. DOI: 10.1038/s41571-021-00518-9. View

Wagner D, Fritsche E, Pulsipher M, Ahmed N, Hamieh M, Hegde M . Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021; 18(6):379-393. PMC: 8923136. DOI: 10.1038/s41571-021-00476-2. View

Cao X, Zhang L, Shi Y, Sun Y, Dai S, Guo C . Human tumor necrosis factor (TNF)-alpha-induced protein 8-like 2 suppresses hepatocellular carcinoma metastasis through inhibiting Rac1. Mol Cancer. 2013; 12(1):149. PMC: 4176125. DOI: 10.1186/1476-4598-12-149. View

10.

Li T, Wang W, Gong S, Sun H, Zhang H, Yang A . Genome-wide analysis reveals TNFAIP8L2 as an immune checkpoint regulator of inflammation and metabolism. Mol Immunol. 2018; 99:154-162. PMC: 5995464. DOI: 10.1016/j.molimm.2018.05.007. View

11.

Sjostedt E, Zhong W, Fagerberg L, Karlsson M, Mitsios N, Adori C . An atlas of the protein-coding genes in the human, pig, and mouse brain. Science. 2020; 367(6482). DOI: 10.1126/science.aay5947. View

12.

Malta T, Sokolov A, Gentles A, Burzykowski T, Poisson L, Weinstein J . Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell. 2018; 173(2):338-354.e15. PMC: 5902191. DOI: 10.1016/j.cell.2018.03.034. View

13.

Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q . TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020; 48(W1):W509-W514. PMC: 7319575. DOI: 10.1093/nar/gkaa407. View

14.

Andrews M, Duong C, Gopalakrishnan V, Iebba V, Chen W, Derosa L . Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021; 27(8):1432-1441. PMC: 11107795. DOI: 10.1038/s41591-021-01406-6. View

15.

Bi J, Cheng C, Zheng C, Huang C, Zheng X, Wan X . TIPE2 is a checkpoint of natural killer cell maturation and antitumor immunity. Sci Adv. 2021; 7(38):eabi6515. PMC: 8443187. DOI: 10.1126/sciadv.abi6515. View

16.

Pare L, Pascual T, Segui E, Teixido C, Gonzalez-Cao M, Galvan P . Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. Ann Oncol. 2018; 29(10):2121-2128. DOI: 10.1093/annonc/mdy335. View

17.

Sun H, Gong S, Carmody R, Hilliard A, Li L, Sun J . TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell. 2008; 133(3):415-26. PMC: 2398615. DOI: 10.1016/j.cell.2008.03.026. View

18.

Good C, Aznar M, Kuramitsu S, Samareh P, Agarwal S, Donahue G . An NK-like CAR T cell transition in CAR T cell dysfunction. Cell. 2021; 184(25):6081-6100.e26. PMC: 8827167. DOI: 10.1016/j.cell.2021.11.016. View

19.

Zhang X, Wang J, Fan C, Li H, Sun H, Gong S . Crystal structure of TIPE2 provides insights into immune homeostasis. Nat Struct Mol Biol. 2008; 16(1):89-90. DOI: 10.1038/nsmb.1522. View

20.

Nassar D, Blanpain C . Cancer Stem Cells: Basic Concepts and Therapeutic Implications. Annu Rev Pathol. 2016; 11:47-76. DOI: 10.1146/annurev-pathol-012615-044438. View